NKGen Biotech

NKGen Biotech Days Payable Outstanding

The Days Payable Outstanding (DPO) of NKGen Biotech (NKGN) as of Nov 22, 2026 is 3,349.63. In the previous year, Days Payable Outstanding (DPO) was 19,770.83 — a change of -83.06% (lower).

Days Payable Outstanding

3,349.63

YoY

-83.06%

Last updated:

Days Payable Outstanding (DPO) of NKGen Biotech is 2023 3,349.63 . Days Payable Outstanding (DPO) of NKGen Biotech was 2022 19,770.83 . It decreases by -83.06% lower compared to the previous year.

The NKGen Biotech Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2021
20,853.67 USD
Jan 1, 2022
19,770.83 USD
Jan 1, 2023
3,349.63 USD
The NKGen Biotech Days Payable Outstanding history
YEARDays Payable OutstandingYoY
3,349.63-83.06%
19,770.83-5.19%
20,853.67—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech Stock analysis

What does NKGen Biotech do? NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage. NKGen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NKGen Biotech stock

Days Payable Outstanding (DPO) of NKGen Biotech is 3,349.63 in 2023.

Days Payable Outstanding (DPO) of NKGen Biotech changed from 19,770.83 to 3,349.63, representing a -83.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) NKGen Biotech since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s NKGen Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — NKGen Biotech

All Key Metrics — NKGen Biotech